Bazedoxifene, a selective estrogen receptor modulator
Authors:
- David F. ArcherDADavid F. Archer
- JoAnn V. PinkertonJPJoAnn V. Pinkerton
- Wulf H. UtianWUWulf H. Utian
- José C. MenegociJMJosé C. Menegoci
- Tobie J. de VilliersTVTobie J. de Villiers
- Chui Kin YuenCYChui Kin Yuen
- Amy B. LevineALAmy B. Levine
- Arkadi A. ChinesACArkadi A. Chines
- Ginger D. ConstantineGCGinger D. Constantine
- 1 November 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Menopause
- Vol. 16 (6) , 1109-1115
Abstract
The aim of this study was to evaluate the endometrial, ovarian, and breast safety of bazedoxifene used as a treatment for postmenopausal osteoporosis. Healthy women (aged 55-85 y) with osteoporosis were enrolled in a randomized, double-blind, placebo-controlled phase 3 trial. Participants were randomized to treatment with bazedoxifene 20 or 40 mg, raloxifene 60 mg, or placebo daily for 3 years. Endometrial and ovarian safety was assessed by periodic transvaginal ultrasonography and endometrial biopsy through 24 months. Gynecologic and breast-related adverse events were recorded throughout the study. Among 753 participants with available transvaginal ultrasonography data, there were no significant between-group differences in overall endometrial thickness or in the percentage of participants with endometrial thickness greater than 5 mm at 12 or 24 months. Changes in the mean endometrial thickness (+/-SE) from baseline were -0.07 +/- 0.11 mm (bazedoxifene 20 mg), 0.10 +/- 0.11 mm (bazedoxifene 40 mg), 0.16 +/- 0.12 mm (raloxifene 60 mg), and -0.08 +/- 0.11 mm (placebo) at 24 months. There was one report of endometrial hyperplasia in each group, and there were zero, two, two, and three reports of endometrial carcinoma with bazedoxifene 20 and 40 mg, raloxifene 60 mg, and placebo, respectively. There were no clinically important changes from baseline in the number or size of ovarian cysts among groups. There was a significantly lower incidence of fibrocystic breast disease (P <or= 0.05) with bazedoxifene compared with raloxifene 60 mg. Bazedoxifene was associated with a favorable endometrial, ovarian, and breast safety profile in postmenopausal women with osteoporosis.Keywords
This publication has 24 references indexed in Scilit:
- Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled StudyJournal of Bone and Mineral Research, 2008
- What can be learned from the levormeloxifene experience?Acta Obstetricia et Gynecologica Scandinavica, 2006
- Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved SelectivityEndocrinology, 2005
- Endometrial Effects of Bazedoxifene Acetate, a Novel Selective Estrogen Receptor Modulator, in Postmenopausal WomenObstetrics & Gynecology, 2005
- Hormone replacement therapy: to use or not to use?Medical Journal of Australia, 2003
- Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment studyAmerican Journal of Obstetrics and Gynecology, 2002
- Developing a SERM: Stringent Preclinical Selection Criteria Leading to an Acceptable Candidate (WAY‐140424) for Clinical EvaluationAnnals of the New York Academy of Sciences, 2001
- Design, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole EstrogensJournal of Medicinal Chemistry, 2001
- Interim Report and Recommendations of the World Health Organization Task-Force for OsteoporosisOsteoporosis International, 1999
- Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene.Journal of Ultrasound in Medicine, 1999